299 related articles for article (PubMed ID: 33446148)
21. Real-world treatment and outcomes of patients with metastatic BRAF mutant colorectal cancer.
Xu T; Li J; Wang Z; Zhang X; Zhou J; Lu Z; Shen L; Wang X
Cancer Med; 2023 May; 12(9):10473-10484. PubMed ID: 36912150
[TBL] [Abstract][Full Text] [Related]
22. BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis.
Cremolini C; Di Bartolomeo M; Amatu A; Antoniotti C; Moretto R; Berenato R; Perrone F; Tamborini E; Aprile G; Lonardi S; Sartore-Bianchi A; Fontanini G; Milione M; Lauricella C; Siena S; Falcone A; de Braud F; Loupakis F; Pietrantonio F
Ann Oncol; 2015 Oct; 26(10):2092-7. PubMed ID: 26153495
[TBL] [Abstract][Full Text] [Related]
23. Final results of the CAVE trial in RAS wild type metastatic colorectal cancer patients treated with cetuximab plus avelumab as rechallenge therapy: Neutrophil to lymphocyte ratio predicts survival.
Ciardiello D; Famiglietti V; Napolitano S; Esposito L; Pietrantonio F; Avallone A; Maiello E; Cremolini C; Troiani T; Martinelli E; Ciardiello F; Martini G
Clin Colorectal Cancer; 2022 Jun; 21(2):141-148. PubMed ID: 35101346
[TBL] [Abstract][Full Text] [Related]
24. RAS/BRAF Circulating Tumor DNA Mutations as a Predictor of Response to First-Line Chemotherapy in Metastatic Colorectal Cancer Patients.
Yao J; Zang W; Ge Y; Weygant N; Yu P; Li L; Rao G; Jiang Z; Yan R; He L; Yu Y; Jin M; Cheng G; An G
Can J Gastroenterol Hepatol; 2018; 2018():4248971. PubMed ID: 29707525
[TBL] [Abstract][Full Text] [Related]
25. Treatment of metastatic colorectal cancer with BRAF V600E mutation: A multicenter real-world study in China.
Xu Y; Wang G; Zheng X; Chang W; Fu J; Zhang T; Lin Q; Lv Y; Zhu Z; Tang W; Xu J
Eur J Surg Oncol; 2023 Nov; 49(11):106981. PubMed ID: 37455182
[TBL] [Abstract][Full Text] [Related]
26. Real-world treatment patterns and survival of patients with BRAF V600-mutated metastatic non-small cell lung cancer.
Horn L; Bauml J; Forde PM; Davis KL; Myall NJ; Sasane M; Dalal A; Culver K; Wozniak AJ; Baik CS; Mutebi A; Zhang P; Wakelee HA; Johnson BE
Lung Cancer; 2019 Feb; 128():74-90. PubMed ID: 30642457
[TBL] [Abstract][Full Text] [Related]
27. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios predict chemotherapy outcomes and prognosis in patients with colorectal cancer and synchronous liver metastasis.
Wu Y; Li C; Zhao J; Yang L; Liu F; Zheng H; Wang Z; Xu Y
World J Surg Oncol; 2016 Nov; 14(1):289. PubMed ID: 27852294
[TBL] [Abstract][Full Text] [Related]
28. The BEETS (JACCRO CC-18) trial: an observational and translational study of
Inagaki C; Matoba R; Yuki S; Shiozawa M; Tsuji A; Inoue E; Muro K; Ichikawa W; Fujii M; Sunakawa Y
Future Oncol; 2023 Jun; 19(17):1165-1174. PubMed ID: 37458152
[TBL] [Abstract][Full Text] [Related]
29. Response to Anti-EGFR Therapy in Patients with BRAF non-V600-Mutant Metastatic Colorectal Cancer.
Yaeger R; Kotani D; Mondaca S; Parikh AR; Bando H; Van Seventer EE; Taniguchi H; Zhao H; Thant CN; de Stanchina E; Rosen N; Corcoran RB; Yoshino T; Yao Z; Ebi H
Clin Cancer Res; 2019 Dec; 25(23):7089-7097. PubMed ID: 31515458
[TBL] [Abstract][Full Text] [Related]
30. Optimization of
Santos C; Azuara D; Garcia-Carbonero R; Alfonso PG; Carrato A; Elez ME; Gomez A; Losa F; Montagut C; Massuti B; Navarro V; Varela M; Lopez-Doriga A; Moreno V; Valladares M; Manzano JL; Vieitez JM; Aranda E; Sanjuan X; Tabernero J; Capella G; Salazar R
Mol Cancer Ther; 2017 Sep; 16(9):1999-2007. PubMed ID: 28626084
[TBL] [Abstract][Full Text] [Related]
31. A validated prognostic classifier for
Loupakis F; Intini R; Cremolini C; Orlandi A; Sartore-Bianchi A; Pietrantonio F; Pella N; Spallanzani A; Dell'Aquila E; Scartozzi M; De Luca E; Rimassa L; Formica V; Leone F; Calvetti L; Aprile G; Antonuzzo L; Urbano F; Prenen H; Negri F; Di Donato S; Buonandi P; Tomasello G; Avallone A; Zustovich F; Moretto R; Antoniotti C; Salvatore L; Calegari MA; Siena S; Morano F; Ongaro E; Cascinu S; Santini D; Ziranu P; Schirripa M; Buggin F; Prete AA; Depetris I; Biason P; Lonardi S; Zagonel V; Fassan M; Di Maio M
Eur J Cancer; 2019 Sep; 118():121-130. PubMed ID: 31330487
[TBL] [Abstract][Full Text] [Related]
32. Encorafenib plus cetuximab treatment in BRAF V600E-mutated metastatic colorectal cancer patients pre-treated with an anti-EGFR: An AGEO-GONO case series.
Hafliger E; Boccaccino A; Lapeyre-Prost A; Perret A; Gallois C; Antista M; Pilla L; Lecomte T; Scartozzi M; Soularue E; Salvatore L; Bourgeois V; Salati M; Tougeron D; Evesque L; Vaillant JN; El-Khoury R; Lonardi S; Cremolini C; Taieb J
Eur J Cancer; 2022 Jun; 168():34-40. PubMed ID: 35436675
[TBL] [Abstract][Full Text] [Related]
33. RAC1b overexpression correlates with poor prognosis in KRAS/BRAF WT metastatic colorectal cancer patients treated with first-line FOLFOX/XELOX chemotherapy.
Alonso-Espinaco V; Cuatrecasas M; Alonso V; Escudero P; Marmol M; Horndler C; Ortego J; Gallego R; Codony-Servat J; Garcia-Albeniz X; Jares P; Castells A; Lozano JJ; Rosell R; Maurel J
Eur J Cancer; 2014 Jul; 50(11):1973-81. PubMed ID: 24833563
[TBL] [Abstract][Full Text] [Related]
34. Characteristics of
de la Fouchardière C; Cohen R; Malka D; Guimbaud R; Bourien H; Lièvre A; Cacheux W; Artru P; François E; Gilabert M; Samalin-Scalzi E; Zaanan A; Hautefeuille V; Rousseau B; Senellart H; Coriat R; Flippot R; Desseigne F; Lardy-Cleaud A; Tougeron D
Oncologist; 2019 Dec; 24(12):e1331-e1340. PubMed ID: 31152084
[TBL] [Abstract][Full Text] [Related]
35. Survival comparison of first-line treatment regimens in patients with braf-mutated advanced colorectal cancer: a multicenter retrospective study.
Meng Q; Zhao J; Yu Y; Wang K; Ren J; Xu C; Wang Y; Wang G
BMC Cancer; 2023 Feb; 23(1):191. PubMed ID: 36849918
[TBL] [Abstract][Full Text] [Related]
36. BRAF mutations, microsatellite instability status and cyclin D1 expression predict metastatic colorectal patients' outcome.
Saridaki Z; Papadatos-Pastos D; Tzardi M; Mavroudis D; Bairaktari E; Arvanity H; Stathopoulos E; Georgoulias V; Souglakos J
Br J Cancer; 2010 Jun; 102(12):1762-8. PubMed ID: 20485284
[TBL] [Abstract][Full Text] [Related]
37. Value of KRAS, BRAF, and PIK3CA Mutations and Survival Benefit from Systemic Chemotherapy in Colorectal Peritoneal Carcinomatosis.
Sasaki Y; Hamaguchi T; Yamada Y; Takahashi N; Shoji H; Honma Y; Iwasa S; Okita N; Takashima A; Kato K; Nagai Y; Taniguchi H; Boku N; Ushijima T; Shimada Y
Asian Pac J Cancer Prev; 2016; 17(2):539-43. PubMed ID: 26925640
[TBL] [Abstract][Full Text] [Related]
38.
Jones JC; Renfro LA; Al-Shamsi HO; Schrock AB; Rankin A; Zhang BY; Kasi PM; Voss JS; Leal AD; Sun J; Ross J; Ali SM; Hubbard JM; Kipp BR; McWilliams RR; Kopetz S; Wolff RA; Grothey A
J Clin Oncol; 2017 Aug; 35(23):2624-2630. PubMed ID: 28486044
[TBL] [Abstract][Full Text] [Related]
39. Health-related quality of life in patients with metastatic colorectal cancer, association with systemic inflammatory response and RAS and BRAF mutation status.
Thomsen M; Guren MG; Skovlund E; Glimelius B; Hjermstad MJ; Johansen JS; Kure E; Sorbye H; Pfeiffer P; Christoffersen T; Guren TK; Tveit KM
Eur J Cancer; 2017 Aug; 81():26-35. PubMed ID: 28595137
[TBL] [Abstract][Full Text] [Related]
40.
Garcia-Carbonero N; Martinez-Useros J; Li W; Orta A; Perez N; Carames C; Hernandez T; Moreno I; Serrano G; Garcia-Foncillas J
Cells; 2020 Jan; 9(1):. PubMed ID: 31952366
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
